LucyRx Chief Executive Officer David Blair was recently featured in SIIA’s The Self-Insurer, where he spoke with reporter Bruce Shutan about the intersection of GLP-1 medications and member education.
In the article, Blair notes that while 40% of LucyRx employer clients currently cover GLP-1s, that number could reach 100% in a few years.
With GLP-1 oral agents already in clinical trials and job candidates increasingly inquiring about coverage, Blair predicts that employers will feel increased pressure to make GLP-1s more readily available.
“We’ve had employers specifically tell us that when they recruit talent, they ask if GLP-1s are covered,” Blair says in the article. He also details the costly risk for employers. “We can’t put individuals on a roughly $1,000 a month drug in perpetuity,” and highlights one approach PBMs can take: requiring members who want to start GLP-1 therapies to commit to lifestyle changes before they’re prescribed in hopes of establishing sustainable weight loss based on greater health literacy.
Share